drugset / Trial / NCT01435226
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection.
Timeline
- Start
- 2011-09
- Primary completion
- 2013-01
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ribavirin | Small molecule | 1000 mg | — |
| Comparator | Ribavirin | Small molecule | 1200 mg | — |
| Comparator | Tegobuvir | Small molecule | 30 mg | — |
| Comparator | Ledipasvir | Small molecule | 90 mg | — |
| Comparator | vedroprevir | Small molecule | 200 mg | — |